GlassScriptPhysician profile
Stephen P Hinton
NPI 1891922472
$2,922.19
in general payments reported to CMS, 2019-2025
16 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,384 · 2020: $59.30 · 2021: $149 · 2022: $100 · 2023: $285 · 2024: $435 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116 · Entertainment: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.14 |
| Entertainment | $114.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,645.74 | 2019-2025 | Clareon, Rocklatan |
| Abbvie INC. | $177.73 | 2023-2025 | |
| Oyster Point Pharma, INC. | $154.04 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $149.22 | 2019-2020 | |
| Optos, INC. | $131.65 | 2020-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $113.70 | 2025 | Xdemvy |
| Dompe US, INC. | $95.26 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $81.18 | 2022-2024 | Cequa |
| Biotissue Holdings INC. | $77.79 | 2023-2024 | |
| Rxsight INC | $72.60 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Mallinckrodt Hospital Products INC. | $61.79 | 2024-2025 | Acthar |
| Glaukos Corporation | $58.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $40.67 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $27.78 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $19.48 | 2025 | Xiidra, Miebo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $15.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hinton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.